Last reviewed · How we verify
Test group: L-oxiracetam Injection
L-oxiracetam enhances neuronal membrane fluidity and facilitates neurotransmitter function, potentially improving cognitive and neurological outcomes.
L-oxiracetam enhances neuronal membrane fluidity and facilitates neurotransmitter function, potentially improving cognitive and neurological outcomes. Used for Cognitive impairment and memory disorders, Age-related cognitive decline, Cerebrovascular insufficiency.
At a glance
| Generic name | Test group: L-oxiracetam Injection |
|---|---|
| Sponsor | Nanjing Yoko Biomedical Co., Ltd. |
| Drug class | Nootropic agent / Pyrrolidone derivative |
| Modality | Small molecule |
| Therapeutic area | Neurology / Cognitive disorders |
| Phase | Phase 3 |
Mechanism of action
L-oxiracetam is a pyrrolidone derivative that is believed to modulate membrane properties and enhance synaptic plasticity. It may improve oxygen utilization and energy metabolism in the brain, supporting neuroprotection and cognitive enhancement. The exact molecular mechanisms remain incompletely characterized but likely involve membrane stabilization and enhancement of neuronal signaling.
Approved indications
- Cognitive impairment and memory disorders
- Age-related cognitive decline
- Cerebrovascular insufficiency
Common side effects
- Headache
- Dizziness
- Gastrointestinal disturbance
- Insomnia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: